Isofol Medical AB (publ) (STO:ISOFOL)

Sweden flag Sweden · Delayed Price · Currency is SEK
2.180
+0.120 (5.83%)
Mar 25, 2025, 1:59 PM CET
213.22%
Market Cap 333.53M
Revenue (ttm) n/a
Net Income (ttm) -43.49M
Shares Out 161.52M
EPS (ttm) -0.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 681,153
Average Volume 373,030
Open 2.060
Previous Close 2.060
Day's Range 2.020 - 2.240
52-Week Range 0.636 - 4.885
Beta 1.93
RSI 67.29
Earnings Date May 21, 2025

About Isofol Medical AB

Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 5
Stock Exchange Nasdaq Stockholm
Ticker Symbol ISOFOL
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.